Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents

Bina Patel,Julia C. Greenland,Caroline H. Williams-Gray
DOI: https://doi.org/10.3233/jpd-240353
2024-09-28
Journal of Parkinson s Disease
Abstract:Inflammation and immune dysregulation have been linked to the pathogenesis and progression of Parkinson's disease (PD), and represent an attractive target for therapeutic intervention, given the potential for repurposing of existing anti-inflammatory and immunomodulatory agents. Despite the fact that initial studies of drugs with secondary anti-inflammatory effects did not yield positive results, agents specifically targeting immune and inflammatory pathways may hold more promise. This article will briefly review the evidence base for targeting the immune system and neuroinflammation in PD, and discuss in detail the recently completed and currently active trials of primary anti-inflammatory/immunomodulatory drugs in PD.
neurosciences
What problem does this paper attempt to address?